Wall Street analysts forecast that Catalent (NYSE:CTLT) will report sales of $610.64 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Catalent’s earnings, with estimates ranging from $599.58 million to $622.50 million. Catalent reported sales of $532.60 million during the same quarter last year, which indicates a positive year-over-year growth rate of 14.7%. The company is scheduled to report its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Catalent will report full-year sales of $610.64 million for the current year, with estimates ranging from $2.44 billion to $2.47 billion. For the next year, analysts expect that the company will post sales of $2.66 billion per share, with estimates ranging from $2.53 billion to $2.76 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The business had revenue of $606.30 million for the quarter, compared to the consensus estimate of $565.05 million. During the same period last year, the business earned $0.27 EPS. The firm’s revenue was up 25.3% compared to the same quarter last year.
Shares of CTLT stock traded down $0.10 during trading on Friday, reaching $40.16. The company had a trading volume of 126,817 shares, compared to its average volume of 890,483. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. Catalent has a one year low of $27.48 and a one year high of $47.87. The company has a market capitalization of $5,266.09, a price-to-earnings ratio of 24.69, a PEG ratio of 2.15 and a beta of 1.53.
In other news, SVP William Downie sold 9,082 shares of Catalent stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total transaction of $379,627.60. Following the sale, the senior vice president now owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.70% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in CTLT. American Century Companies Inc. boosted its stake in Catalent by 755.3% in the 4th quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock valued at $108,108,000 after buying an additional 2,323,971 shares in the last quarter. Redmile Group LLC boosted its stake in Catalent by 464.2% in the 4th quarter. Redmile Group LLC now owns 833,063 shares of the company’s stock valued at $34,222,000 after buying an additional 685,400 shares in the last quarter. Carillon Tower Advisers Inc. acquired a new stake in Catalent in the 4th quarter valued at $27,561,000. Hood River Capital Management LLC acquired a new stake in Catalent in the 4th quarter valued at $16,283,000. Finally, Champlain Investment Partners LLC boosted its stake in Catalent by 10.9% in the 4th quarter. Champlain Investment Partners LLC now owns 3,043,715 shares of the company’s stock valued at $125,036,000 after buying an additional 298,015 shares in the last quarter. 99.89% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://stocknewstimes.com/2018/04/18/610-64-million-in-sales-expected-for-catalent-ctlt-this-quarter.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.